01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – MSD to acquire Cidara November 27, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates its client Cidara Therapeutics, Inc (“Cidara” or the “partner”) which has entered into a definitive agreement under which Merck Sharp & Dohme LLC (“MSD”), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO’s unique capabilities in accelerating drug development and validates the…

Continue reading

#HVO hVIVO PLC – Notice of Trading Update July 9, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30 June 2025 on Tuesday 22 July 2025.   Investor presentation   Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Tuesday 22 July 2025…

Continue reading

#HVO hVIVO PLC – Positive results from RSV human challenge trial October 7, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals (“Enanta”), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate.   EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has…

Continue reading

#HVO hVIVO PLC – £2.5m contract for Omicron characterisation study June 3, 2024 – Posted in: hVIVO (HVO)

• Characterisation study to establish world’s first Omicron BA.5 challenge model • Study to utilise hVIVO’s new state-of-the-art containment level 3 (CL3) quarantine facilities in Canary Wharf • FluCamp to recruit healthy 18-30 year old seropositive volunteers who have previously completed a course of COVID-19 vaccination • New quarantine unit in Canary Wharf facilitates the expansion of hVIVO’s world leading portfolio of human challenge models   hVIVO plc (AIM & Euronext: HVO), a fast growing…

Continue reading

#HVO hVIVO PLC – £6.8m RSV human challenge contract signed February 6, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.8m contract with a leading pharmaceutical company based in Asia Pacific (“APAC”), to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model.                                 The Phase 2a double-blinded placebo-controlled…

Continue reading

#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development November 18, 2021 – Posted in: Blog, Poolbeg Pharma (POLB)

18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The Company intends to commence the Phase Ib human challenge study of POLB 001 in June 2022 which will be a key step in…

Continue reading